# David Preiss

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-preiss/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,527 |
| Field | Lipoproteins and Cardiovascular Health |
| h-index | 60 |
| i10-index | 103 |
| Last Known Institution | University of Oxford |
| OpenAlex ID | https://openalex.org/A5039985378 |
| ORCID iD | https://orcid.org/0000-0003-3139-1836 |
| Works | 218 |

## Researcher papers

- [Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials](https://scholariq.org/papers/statins-and-risk-of-incident-diabetes-a-collaborative-meta-analysis-of/)
- [Interpretation of the evidence for the efficacy and safety of statin therapy](https://scholariq.org/papers/interpretation-of-the-evidence-for-the-efficacy-and-safety-of-statin-therapy/)
- [Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials](https://scholariq.org/papers/cardiovascular-mortality-and-kidney-outcomes-with-glp-1-receptor-agonists-in/)
- [Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials](https://scholariq.org/papers/impact-of-diabetes-on-the-effects-of-sodium-glucose-co-transporter-2-inhibitors/)
- [Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials](https://scholariq.org/papers/efficacy-and-safety-of-statin-therapy-in-older-people-a-meta-analysis-of/)
- [HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials](https://scholariq.org/papers/hmg-coenzyme-a-reductase-inhibition-type-2-diabetes-and-bodyweight-evidence-from/)
- [Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk](https://scholariq.org/papers/carotid-intima-media-thickness-progression-as-surrogate-marker-for/)
- [Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/risk-related-to-pre-diabetes-mellitus-and-diabetes-mellitus-in-heart-failure/)
- [SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?](https://scholariq.org/papers/sglt2-inhibition-and-cardiovascular-events-why-did-empa-reg-outcomes-surprise/)
- [The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study](https://scholariq.org/papers/the-potential-for-improving-cardio-renal-outcomes-by-sodium-glucose-co/)
- [Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis](https://scholariq.org/papers/effect-of-mineralocorticoid-receptor-antagonists-on-proteinuria-and-progression/)
- [Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction](https://scholariq.org/papers/clinical-and-echocardiographic-characteristics-and-cardiovascular-outcomes/)

## Researcher topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)

## Researcher university

- [University of Oxford](https://scholariq.org/institutions/university-of-oxford/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.